AI Article Synopsis
- The radiopharmaceutical FDG has been a key player in PET scans for over 20 years and is used in various medical fields like oncology and neurology.
- The integration of AI has improved the accuracy of imaging and diagnosis with FDG-PET, and new radiopharmaceuticals like PSMA and FAPI are being developed.
- Recent advances in nuclear medicine, including therapies like [Lu]-dotatate, show better results compared to traditional treatments, prompting a review of current evidence and future directions in the field.
Article Abstract
The radiopharmaceutical 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) has been dominantly used in positron emission tomography (PET) scans for over 20 years, and due to its vast utility its applications have expanded and are continuing to expand into oncology, neurology, cardiology, and infectious/inflammatory diseases. More recently, the addition of artificial intelligence (AI) has enhanced nuclear medicine diagnosis and imaging with FDG-PET, and new radiopharmaceuticals such as prostate-specific membrane antigen (PSMA) and fibroblast activation protein inhibitor (FAPI) have emerged. Nuclear medicine therapy using agents such as [Lu]-dotatate surpasses conventional treatments in terms of efficacy and side effects. This article reviews recently established evidence of FDG and non-FDG drugs and anticipates the future trajectory of nuclear medicine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12149-023-01865-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!